Skip to main content

Issue Archive

Scroll to View Archive

March 2024 Vol 17, No 2

  • Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials

    Chemotherapy is the standard-of-care treatment for advanced biliary tract cancer (BTC); however, outcomes are poor, and there is no clear standard treatment after first-line therapies. Brigimadlin (BI 907828) is a highly potent, orally administered MDM2-p53 antagonist that inhibits the interaction between TP53 and its negative regulator, MDM2. Therefore, TP53 wild-type tumors exhibit cell cycle arrest or apoptosis
  • Incidence of Colorectal Cancer Rising in Young Adults

    Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years. In recent years, the diagnosis of CRC has been shifting to a younger age and a more advanced stage. In fact, 1 in 5 new cases of CRC occurs in people aged <50, and more individuals are diagnosed at an advanced stage now than in the mid-1990s before widespread screening.

    The award-winning documentary Of Medicine and Miracles follows oncologist and Breakthrough Prize winner Dr Carl June of the University of Pennsylvania as he takes on the impossible: finding a cure for cancer.